FVR Suomen rokotetutkimus Oy
- Address
- lock Available on a paid plan
Respiratory Virus Prevention and Immune System Research
At FVR Suomen rokotetutkimus Oy in Oulu, clinical research focuses on protecting people from respiratory syncytial virus (RSV) and other viral respiratory illnesses. These studies explore how well new preventive approaches work and how safe they are for infants, children, and other at-risk groups.
- Prevention of RSV infection in infants and children at increased risk of severe disease
- Evaluation of MK-1654 for safety and effectiveness in reducing RSV-related lower respiratory illness
- Comparison of RSV prevention approaches against established care options
The research aims to improve protection against serious virus diseases while strengthening understanding of immune system processes involved in infection prevention.
Influenza Vaccine Studies
This site also conducts trials in respiratory tract diseases and virus diseases centered on influenza. The work evaluates whether vaccines can better prevent seasonal flu in older adults and support stronger public health protection.
- Prevention of influenza A and B disease in adults aged 65 and older
- Assessment of vaccine effectiveness against circulating influenza strains
- Safety and tolerability of influenza immunization strategies
These studies are designed to test the value of new or improved influenza vaccines in reducing illness and supporting protection in older populations.
Pneumococcal Disease Research
Clinical trials at the Oulun rokotetutkimusklinikka include work on bacterial infections, especially pneumococcal infections in young children. The research is focused on understanding vaccine safety and immune response in early childhood.
- Study of a pneumococcal conjugate candidate in healthy toddlers
- Evaluation of safety in children receiving a preventive vaccine series
- Support for better protection against serious bacterial respiratory infections
Overall, these studies aim to improve prevention of pneumococcal disease and help guide future vaccination strategies for children.
Preventive Antibody and Vaccine Safety Studies
Another major theme at this research site is the evaluation of preventive medicines and vaccines for children at higher risk of severe respiratory illness. These trials examine both protection and tolerability, helping determine whether new options can reduce disease burden safely.
- Safety and tolerability assessments for RSV-targeted preventive therapy
- Comparison with established prevention methods for high-risk infants and children
- Monitoring of adverse events and overall treatment acceptability
The goal is to support better prevention of respiratory syncytial virus and related complications through improved clinical trial evidence.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in FVR Suomen rokotetutkimus Oy
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants | Merck Sharp & Dohme LLC | Phase IV | Not Recruiting | Nov 2022 | Feb 2024 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227) | 1 | Unknown | 2023-10-20 | 2023-10-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.